Journal
JOURNAL OF MEDICINAL CHEMISTRY
Volume 54, Issue 19, Pages 6714-6723Publisher
AMER CHEMICAL SOC
DOI: 10.1021/jm2005892
Keywords
-
Categories
Funding
- Deutsche Forschungsgemeinschaft [BI 1044/2-2]
- Europrofession Foundation (Saarbrucken, Germany)
- Deutsche Jose Carreras Leukamie-Stiftung (DJCLS) [R 06/07]
- German Federal Ministry of Education and Science
Ask authors/readers for more resources
Protein kinase inhibitors with an allosteric mode of action are expected to reach, in many cases, higher selectivity for the target enzyme than ATP-competitive compounds. Therefore, basic research is aiming at identifying and establishing novel sites on the catalytic domain of protein kinases which might be targeted by allosteric inhibitors. We previously published the first structure-activity relationships (SARs) for allosteric activators of protein kinase PDK1. Here, we present the design, synthesis, and SAR data on a series of novel compounds, 4-benzimidazolyl-3-phenylbutanoic acids, that inhibit the atypical protein kinace C (PKC) zeta via binding to the PIF-pocket. Key positions were identified in the compounds that can be modified to increase potency and selectivity. Some congeners showed a high selectivity toward PKC zeta, lacking inhibition of the most closely related isoform, PKCl, and of further AGC kinases. Furthermore, evidence is provided that these compounds are also active toward cellular PKC zeta without loss of potency compared to the cell-free assay.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available